
==== Front
Rom J Morphol Embryol
Rom J Morphol Embryol
RJME
Romanian Journal of Morphology and Embryology
1220-0522
2066-8279
Academy of Medical Sciences, Romanian Academy Publishing House, Bucharest

39020537
650224225241
10.47162/RJME.65.2.09
Original Paper
A 10-year retrospective study of the risks and peculiarities in pediatric patients with (para)gonadal tumors and cysts
Ataikiru Usiwoma Okeroghene 12
Iacob Emil Radu 12
Heredea Elena Rodica 13
Stănciulescu Maria Corina 12
Galinescu Mihai Codrin 4
Popoiu Călin Marius 12
Boia Eugen Sorin 12
1 Department of Pediatric Surgery and Orthopedics, Victor Babeş University of Medicine and Pharmacy, Timişoara, Romania
2 Department of Pediatric Surgery and Orthopedics, Louis Ţurcanu Emergency Children Hospital, Timişoara, Romania
3 Department of Pathology and Histology, Louis Ţurcanu Emergency Children Hospital, Timişoara, Romania
4 Department of Pediatric Surgery and Orthopedics, Emergency County Hospital, Bacău, Romania
Corresponding Author: Emil Radu Iacob, Associate Professor, MD, PhD Department of Pediatric Surgery and Orthopedics Victor Babeş University of Medicine and Pharmacy 2 Eftimie Murgu Square 300041 Timişoara Romania + 40745–614 590 radueiacob@umft.ro
Apr-Jun 2024
30 6 2024
65 2 225241
10 3 2024
23 6 2024
Copyright © 2024, Academy of Medical Sciences, Romanian Academy Publishing House, Bucharest
2024
https://creativecommons.org/licenses/by-nc-sa/4.0/ This is an open-access article distributed under the terms of a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Public License, which permits unrestricted use, adaptation, distribution and reproduction in any medium, non-commercially, provided the new creations are licensed under identical terms as the original work and the original work is properly cited.
Introduction: Gonadal pediatric tumors are rare, ranking fourth (6%) among pediatric tumors, by Surveillance, Epidemiology, and End Results Program (https://seer.cancer.gov/). They have vague symptoms, leading to late discovery, but early detection and identifying its risk factors result in favorable prognosis and reduction of its incidence respectively. Patients, Material and Methods: A 10-year retrospective study identified peculiarities and risk factors in 210 children till age 17 with (para)gonadal tumors. Results: Stress, pollution (agricultural chemicals, insecticides and metal mine), obesity, breastfeeding ≤5 months, malformations [mainly non-genetic related 67/87 (77%), especially eye malformation – 64%], hormone, smoking, positive heredo-genetic history, rural residence area, abnormal birth weight, and menstruation disorders showed an increased gonadal malignancy risk; relative risk ratio (RR): 1.33, 1.30, 1.34, 1.11, 1.65, 1.16, 1.36, 1.10, 1.00, 1.08 and 1.15 folds, respectively. RR for histopathological subtypes: immature teratoma (IT) (pollution – 1.75, Rhesus positive – 3.41), dysgerminoma (menstruation disorders – 2.80), granulosa cell tumor (stress – 2.10, menstruation disorders – 2.80), mucinous cystadenomas (obesity – 2.84, no postnatal vaccine – 3.71), mature teratomas (stress – 2.35, malformations – 2.18) and serous cystadenomas (breastfeeding ≤5 months – 2.53), dependent variables being mixed germ cell tumors (GCTs) and cysts. Children presenting with bleeding (73%), abdominal distention (62%), elevated tumor markers (91%), (multilocular) solid tumor (88% and 100%), tumor size >10 cm (65%), GCTs (74%), death (100%), metastases (100%), viruses (77%), loss of appetite (68%), and weight (85%), had gonadal malignant tumors, especially mixed GCTs and IT. Conclusions: Avoiding these risk factors will prevent and reduce gonadal pediatric tumors. Investigating children presenting with the listed peculiarities, especially if exposed to the mentioned risk factors, will enable early gonadal tumor identification, successful patient management, and favorable prognosis.

testicular tumor
ovarian tumor
risk factors
gonadal tumor peculiarities
children
==== Body
pmcIntroduction

Pediatric testicular and ovarian tumors are rare, with an incidence rate of 0.3–12:100 000 and 2.6–10.7:100 000, peaking below age one (18:1000 000) and at 15–19 years (28:1000 000) [1, 2, 3, 4, 5]. Although curable with favorable prognosis, this is possible only when discovered early [1, 2, 3, 4, 5]. However, there are obstacles to achieving this, making it a challenge, as gonadal tumors have an unclear multi-etiology and vague manifestation, and hence easily misdiagnosed. This was observed in 70% of women with ovarian tumors who presented late, leading to outcomes like death or infertility [1, 2, 3, 6]. A group of studies showed that the daily cost of hospitalization of pediatric cancer patients is 70% higher than for other diseases, and they stay an average of eight days more in the hospital; also, delayed diagnoses increase patients’ hospital costs [7, 8].

The Romanian Society of Pediatric Onco-Hematology and the National Registry of Childhood Cancers published a 2010–2021 study showing that annually, the prevalence of gonadal and germ cell tumors (GCTs) among other pediatric tumors was 3.4% for 0–14 years, 12.2% for 15–19 years and 5% for 0–19 years [5, 9, 10]. The pediatric cancer patients’ survival in Romania was 72% (2010–2017) for 0–19 years, which is below the mean of European countries (81%); also, the survival rate in children with gonadal and GCTs dropped from 85% (2010–2013) to 81% (2014–2017), and 6% increase was observed in ages 0–14 [9, 10, 11]. Cancer remains the leading cause of disease related death in children, and an increase in the incidence rate and mortality rate from 1975 is recognized, especially in Western countries; also, a 25% increase in the incidence rate is predicted by 2025 in Europe [2, 12, 13]. The incidence rate of testicular and ovarian tumors in Europe is 12% and 10.7%, unlike in North America 8.3% and 8.1%, in Africa 0.3% and 4.9%, and in Asian populations 2.9% and and 8.1%, respectively [1, 2, 4]. World Health Organization (WHO) recently reported that cancer awareness, early detection of pediatric tumors, administering appropriate treatment, and availability of cancer facilities and medications varied significantly between Western and Eastern European countries, leading to a 9–57% mortality rate, varying health of survivors; hence, actions for equality across Europe is required [14].

Aim

Our study, therefore, aims to identify children with (para)gonadal tumors, analyze the peculiar clinical features presented, and evaluate the risk factors to which they were exposed. This will allow us to easily identify malignancy and its histopathological (HP) subtype quickly, possibly before surgery. This will also enable better patient management, favorable prognosis, minimal side effects, and prevention or reduction of childhood tumors by avoiding identified high-risk factors.

Patients, Materials and Methods

We conducted a retrospective study from 2010–2020 of the peculiarities and risk factors of gonadal tumors at Emergency Children Hospitals in Iaşi, Bacău, and Timişoara (Louis Ţurcanu) that attends to pediatric patients from western Romania. The study participants included 210 pediatric patients, with 164 being female, 98 patients had malignant (para)gonadal tumors and 112 had benign tumors. Patients were at prepubertal (one month–nine years) to pubertal ages (10–17 years).

Data

We collected data from patients’ files, questionnaires, and telephone interviews. The data included demographic details, diagnosis, presentations (localization, size, tumor stage, and grade), loculation type, pain location and radiation, prenatal diagnosis, presence of signs and symptoms such as appendicitis, vomiting, constipation, loss of appetite, weight loss, leukocytosis, fever, bleeding, abdominal distention, viral infection, ascites, and urinary tract infection (UTI). We also collected data on the presence of elevated tumor markers, metastasis, recurrence, compressed organs, asymptomatic cases, mortality and gonadectomy. For risks factors, patients’ data was collected included obesity, mother’s age, length of breastfeeding, disorders of sexual development, stress, hormones, smoking, heredo-genetic history, abnormal birthweight, residential area, pollution, Rhesus (Rh) factor, vitamin D, vaccination, menstrual disorders, and malformations.

Informed consent

Informed verbal and written consent was obtained from the participants’ parents.

Ethical approval

The study was performed in compliance with all institutional policies, according to the Helsinki Declaration’s tenets, the World Medical Association (WMA), Romania’s regulations, Medical Research Council Guidelines for Good Clinical Practice in Clinical Trials, WHO Guidelines, and approved by the Timişoara, Iaşi, Arad and Bacău Emergency Children Hospital Ethical Committee (Approval No. 124/2020–16922 on 11.12.2020) and the Scientific Research Ethics Commission (Approval No. 59/12.12.2018).

Tumor markers analysis

We obtained blood (5 mL) from fasting patients before administering any treatment and afterward to verify the patients’ condition. We stored the blood at 25°C for one hour, then centrifuged at 4000 rpm to isolate the blood serum. As per the manufacturer’s directives (Mannheim, Germany), the markers were measured by an electric chemiluminescence analyzer with alpha-fetoprotein (AFP, 9.92 IU/mL), beta-human chorionic gonadotropin (β-HCG, 5.3 IU/l), lactate dehydrogenase (LDH, 0–300 U/L), cancer antigen-125 (CA-125, 0–35 kU/L), carcinoembryonic antigen (CEA, 0–5.3 ng/mL), neuron-specific enolase (NSE, 0–16 ng/mL) and human epididymis protein 4 (HE4, 0–70 pmol/L) kits and cutoff marks were accordingly. Inhibin B hormone, anti-Müllerian hormone (AMH), and estradiol were measured based on age.

Statistical analysis

We used Stata ver. 17 (2021) (StataCorp, Texas, TX, USA) multinomial logistic regression for relative risk ratio (RR), estimation coefficient (β), 95% confidence interval (CI), p-values <0.05, and the results in percentages.

Histopathology study

From the Pathology Service of the Emergency Children Hospitals of Bacău, Iaşi, Arad, and Timişoara, expert pathologists analyzed gonadal tissue specimens macro- and microscopically to identify HP components and determined the diagnoses. An average of two or more sample fragments per patient of testicular or ovarian specimens were harvested by tissue excision, and ≥6 slides per patient underwent Hematoxylin–Eosin (HE) and immunohistochemical (IHC) staining. Fixation of the tissue was performed by placing the sample in a 10% neutral buffered formalin solution for 48 hours. The sample was processed, paraffin-embedded, sectioned into 3 μm sections, deparaffinized, and rehydrated. The sections were then ready for staining using the usual HE technique. Leica Autostainer XL was used for morphological staining (Leica Biosystems Newcastle Ltd., Newcastle upon Tyne, UK). The HE-stained sections were examined on multiple slides with a Leica DM 750 optical microscope and Leica AirLab Microsystems GmbH to identify the HP components. If a rare or suspected malignant tumor was observed, the section was taken for further IHC analysis. Heat-induced epitope retrieval was conducted to retrieve antigen reactivity in the paraffin-embedded sample tissue (formalin-fixed) using the Novocastra mouse monoclonal antibody by Leica Biosystems (Newcastle Ltd., Newcastle upon Tyne, UK). The antibodies, their clones, and dilutions performed at 25°C for 30 minutes, include: anti-cytokeratin 8/18 (CK8/18) (5D3, 1:200), anti-Ki67 (MM1, 1:200), anti-vimentin (V9, 1:800), anti-alpha smooth muscle actin (α-SMA) (αsm-1, 1:50), anti-S100 (EP32, 1:100), anti-placental alkaline phosphatase (PLAP) (8A9, 1:50), anti-cluster of differentiation (CD)10 (56C6, 1:100), anti-octamer-binding protein 3/4 (OCT3/4) (N1NK, 1:100), anti-myogenin (Myf4) (LO26, 1:40), anti-epithelial membrane antigen (EMA) (GP1.4, 1:200), anti-desmin (DE-R-11, 1:200), anti-CD30 (JCM182, 1:100), anti-AFP (C3, 1:100), anti-p53 (DO-7, 1:800) per the manufacturer’s guidelines.

Besides markers, physical and radiological examination, we performed surgical interventions to verify tumor presence for staging, treatment, and postoperative pathology diagnostics. Histopathology using HE staining and IHC played an extremely vital role in investigating and concretely identifying patients with malignancy, from specimen macroscopic and microscopic examination for postoperative staging and grading; to identify lymph node metastasis, lymphovascular invasion, and retroperitoneal nodal, used in deciding the treatment and estimating patients survival prognoses. Histopathology diagnosis, classification, and staging was done using the WHO Classification of Tumors of the Genital Organs and the Urinary System criteria.

Results

Our study population consisted of 210 patients: 96 had GCTs, nine had sex-cord stromal tumors (SCSTs), 35 had epithelial tumors, and 53 had cysts; also, a patient had a combination of SCSTs and GCTs (gonadoblastoma), another had SCST and epithelial tumor (adenofibroma), while 15 patients had other types of tumors like rhabdomyosarcoma (RMS) and Langerhans cell histiocytosis (LCH) (Figure 1).

Figure 1 Histological types and subtype of (para)gonadal tumors in our study

The male-to-female ratio in this study is 1:1.45; also, the majority of patients presented at stage 2 – 45/98 (46%) and at grade 1 – 39/98 (40%) (Figure 2). Gonadectomy was performed on 27 (24%) patients with benign tumors due to large tumor size, if vital organs are compressed, or in cases of necrotic torsioned gonads. In comparison, nine (9%) patients with malignancy had their gonads spared because of the patient’s and family’s decisions, considering if both gonads were involved, tumor type, stage, grade, and size. Tumor obstruction led to 21% of UTI cases. The patients with viruses in Table 1 had human immunodeficiency virus (HIV), human herpesvirus 1–6, hepatitis, tuberculosis, and rubella. The asymptomatic presentation reported was observed in two boys whose malignant tumors were found coincidentally on admission after involvement in accidents. Of the 35 patients with appendicitis, 54% had their tumor identified during appendicectomy, and for the other 45%, the reverse was the case.

Figure 2 The number of children per tumor stage and grade in our study

Table 1 The peculiarities observed in our study population, for the total number of patients with benign and malignant tumors, accordingly, using percentages [n, (%)] and p-values

Peculiarities

	Total

	Malignant tumors

	Bening tumors

	p -value

	
Tumor types

	210

	  Total : 98

 IT: 21 (10%)

 RMS: 14 (6.7%)

 DYS: 9 (4.3%)

 Mixed GCT: 26 (12.4%)

 SEM: 2 (1%)

 AC: 5 (2.4%)

 LCH: 1 (0.5%)

 EC: 3 (1.4%)

 GrCT: 6 (2.9%)

 CHOR: 1 (0.5%)

 YST: 10 (4.8%)

	  Total : 112

 Gonadoblastoma: 1 (0.5%)

 SST: 1 (0.5%)

 MT: 24 (11.4)

 Fibroma: 2 (1%)

 AF: 1 (5%)

 MCA: 10 (4.8%)

 SCA: 17 (8.1%)

 BCA: 3 (1.4%)

 Cysts: 53 (25%)

		
Age [years]

					
 Prepuberty (0–9)

	56

	41 (73%)

	15 (27%)

	0.001

	
 Puberty (10–17)

	154

	57 (37%)

	97 (63%)

	
Sex

					
 Male

	47

	40 (85%)

	7 (15%)

	0.001

	
 Female

	163

	58 (36%)

	105 (64%)

	
Size [cm]

					
 <5

	37

	10 (27%)

	27 (73%)

	0.001

	
 5–10

	110

	47 (43%)

	63 (57%)

	
 >10

	63

	41 (65%)

	22 (35%)

	
Tumor location

					
 Right

	79

	32 (41%)

	47 (49%)

	0.373

	
 Left

	110

	55 (50%)

	55 (50%)

	
 Both sides

	21

	11 (52%)

	10 (48%)

	
Pain location

					
 Right

	61

	30 (49%)

	31 (51%)

	0.932

	
 Left

	104

	48 (49%)

	56 (51%)

	
 Both sides

	38

	18 (47%)

	20 (53%)

	
Pain radiates to leg

	53

	26 (49%)

	27 (51%)

	0.687

	
Repetition

	20

	13 (65%)

	7 (35%)

	0.084

	
Death

	4

	4 (100%)

	0 (0%)

	0.031

	
Prenatal diagnosis

	8

	2 (25%)

	6 (75%)

	0.210

	
Gonadectomy

	116

	89 (77%)

	27 (23%)

	0.001

	
Asymptomatic

	7

	2 (29%)

	5 (71%)

	0.329

	
Appendicitis

	35

	16 (46%)

	19 (54%)

	0.901

	
Loss of appetite

	59

	40 (68%)

	19 (32%)

	0.001

	
Loss of weight

	33

	28 (85%)

	5 (15%)

	0.001

	
Leukocytosis

	54

	19 (35%)

	35 (65%)

	0.050

	
Fever

	16

	5 (31%)

	11 (69%)

	0.191

	
Constipation

	21

	13 (62%)

	8 (38%)

	0.140

	
Vomit

	9

	2 (22%)

	7 (78%)

	0.329

	
Bleeding

	26

	19 (73%)

	7 (27%)

	0.001

	
Abdominal distention

	63

	39 (62%)

	24 (38%)

	0.004

	
Ascites

	14

	10 (71%)

	4 (29%)

	0.055

	
GCT

	97

	72 (74%)

	25 (26%)

	0.001

	
Not GCT

	113

	26 (23%)

	87 (77%)

	
Loculation

					
 Unilocular cyst

	39

	0 (0%)

	39 (100%)

	0.001

	
 Unilocular cyst + solid

	22

	2 (9%)

	20 (91%)

	
 Multilocular cyst

	33

	5 (15%)

	28 (85%)

	
 Multilocular cyst + solid

	50

	29 (58%)

	21 (42%)

	
 Multilocular solid

	33

	29 (88%)

	4 (12%)

	
 Solid

	33

	33 (100%)

	0 (0%)

	
Compressed organs

	36

	20 (56%)

	16 (44%)

	0.240

	
Viruses

	26

	20 (77%)

	6 (23%)

	0.001

	
Elevated tumor markers

	88

	80 (91%)

	8 (9%)

	0.001

	
AC: Adenocarcinoma; AF: Adenofibroma; BCA: Borderline cystadenoma; CHOR: Choriocarcinoma; DYS: Dysgerminoma; EC: Embryonal carcinoma; GCT: Germ cell tumor; GrCT: Granulosa cell tumor; IT: Immature teratoma; LCH: Langerhans cell histiocytosis; MCA: Mucinous cystadenoma; MT: Mature teratoma; n: No. of cases; RMS: Rhabdomyosarcoma; SCA: Serous cystadenoma; SEM: Seminoma; SST: Sclerosing stromal tumor; YST: Yolk sac tumor.

The surgical approaches used were open surgery (70%), laparoscopy (24%), and robotic surgery (6%). Additionally, in our study, 34 (16.2%) patients had metastasis, the <5-year overall survival was 32.3% and for >5 years was 66.7%. The elevation of tumor markers among malignant tumor patients is shown in Figure 3. Furthermore, LDH was elevated in two patients with large cysts, three with mature teratoma (MT), a patient with serous cystadenoma (SCA), and another with borderline cystadenoma (BCA); and CA-125 was slightly elevated in three patients with MTs, a patient with SCAs, one with cyst and another with adenofibroma.

Figure 3 Tumor marker elevation in our malignant tumor study population. AFP: Alpha-fetoprotein; AMH: Anti-Müllerian hormone; β-HCG: Beta-human chorionic gonadotropin; LDH: Lactate dehydrogenase; CA-125: Cancer antigen-125; CEA: Carcinoembryonic antigen; NSE: Neuron-specific enolase; HE4: Human epididymis protein 4

Further studies done to identify significant peculiarities in each tumor type are shown in Table 2 and Table 3. Excluding cases where no patient had that peculiar presentation, we observed that the percentage of patients with the mentioned morphology in Table 4, recognized in literature was >60%, except for 25 cases from the 48 peculiarities for each of the 10 malignant tumor types reported (25/480, 5.2%), observed in yolk sac tumor (YST), immature teratoma (IT), dysgerminoma (DYS), RMS, granulosa cell tumor (GrCT). For benign tumors, in Table 5, the exception was eight cases from the 39 peculiarities for each of the nine benign tumor types reported (8/351, 2.3%), observed in patients with SCA, mucinous cystadenoma (MCA) and BCA. The relative risk of getting gonadal malignant tumors with an increase in each unit of the risk factors analyzed is reported in Table 6. Eighty-five percent of the patients who were exposed to pollution reported constant exposure to agricultural chemicals, metal mining, and insecticides. The estimation coefficient (β) showing the chances of getting the different malignant and benign tumor types with an increase in each unit of the risk factors is presented in Table 7 and Table 8; also, patients who had mixed GCT and cysts were used as the dependent variable. Patients with eye malformations 28/87 (32%) was the highest among non-genetic malformations, and disorder of sex development (DSD) 17/28 (60.7%) was the highest among genetic-related malformations (Table 9).

Table 2 The peculiarities observed in the different malignant tumor types found in our study population, using percentages [n, (%)]

Peculiarities of malignant tumors

	Total

	YST

	Mixed GCT

	IT

	DYS

	SEM

	AC

	CHOR

	RMS

	EC

	LCH

	GrCT

	
Age [years]

													
 Prepuberty (0–9)

	42

	6 (14.3%)

	9 (22%)

	9 (22%)

	2 (5%)

	0 (0%)

	2 (5%)

	0 (0%)

	7 (17%)

	2 (5%)

	1 (2%)

	3 (7%)

	
 Puberty (10–17)

	56

	4 (7%)

	17 (30%)

	12 (21%)

	7 (12%)

	2 (4%)

	3 (5%)

	1 (2%)

	7 (12%)

	1 (2%)

	0 (0%)

	3 (5%)

	
Sex

													
 Male

	40

	4 (10%)

	17 (43%)

	7 (18%)

	1 (3%)

	2 (5%)

	0 (0%)

	1 (3%)

	8 (20%)

	0 (0%)

	0 (0%)

	0 (0%)

	
 Female

	58

	6 (10%)

	9 (16%)

	14 (24%)

	8 (14%)

	0 (0%)

	5 (9%)

	0 (0%)

	6 (10%)

	3 (5%)

	1 (2%)

	6 (10%)

	
Size [cm]

													
 <5

	10

	1 (10%)

	1 (10%)

	2 (20%)

	2 (20%)

	0 (0%)

	1 (10%)

	0 (0%)

	2 (20%)

	1 (10%)

	0 (0%)

	0 (0%)

	
 5–10

	47

	4 (9%)

	15 (32%)

	10 (21%)

	4 (9%)

	1 (2%)

	1 (2%)

	1 (2%)

	8 (17%)

	1 (2%)

	1 (2%)

	1 (2%)

	
 >10

	41

	5 (12%)

	10 (24%)

	9 (22%)

	3 (7%)

	1 (2%)

	3 (7%)

	0 (0%)

	4 (10%)

	1 (2%)

	0 (0%)

	5 (12%)

	
Tumor location

													
 Right

	32

	3 (9%)

	9 (28%)

	4 (13%)

	5 (16%)

	1 (3%)

	2 (6%)

	1 (3%)

	6 (19%)

	0 (0%)

	0 (0%)

	1 (3%)

	
 Left

	55

	7 (13%)

	16 (29%)

	15 (27%)

	4 (7%)

	1 (2%)

	1 (2%)

	0 (0%)

	6 (11%)

	2 (4%)

	0 (0%)

	3 (5%)

	
 Both sides

	11

	0 (0%)

	1 (9%)

	2 (18%)

	0 (0%)

	0 (0%)

	2 (18%)

	0 (0%)

	2 (18%)

	1 (9%)

	1 (9%)

	2 (18%)

	
Pain location

													
 Right

	30

	3 (10%)

	8 (27%)

	4 (13%)

	5 (17%)

	1 (3%)

	2 (7%)

	1 (3%)

	5 (17%)

	0 (0%)

	0 (0%)

	1 (3%)

	
 Left

	48

	6 (12%)

	17 (34%)

	13 (26%)

	3 (6%)

	0 (0%)

	1 (2%)

	0 (0%)

	5 (10%)

	2 (4%)

	0 (0%)

	3 (6%)

	
 Both sides

	18

	1 (6%)

	1 (6%)

	4 (22%)

	1 (6%)

	1 (6%)

	2 (11%)

	0 (0%)

	4 (22%)

	1 (6%)

	1 (6%)

	2 (11%)

	
Pain radiates to leg

	26

	3 (6%)

	25 (49%)

	12 (24%)

	2 (4%)

	0 (0%)

	2 (4%)

	0 (0%)

	4 (8%)

	1 (2%)

	0 (0%)

	2 (4%)

	
Repetition

	13

	1 (8%)

	3 (23%)

	1 (8%)

	0 (0%)

	0 (0%)

	2 (15%)

	0 (0%)

	4 (31%)

	1 (8%)

	0 (0%)

	1 (8%)

	
Death

	4

	0 (0%)

	2 (50%)

	0 (0%)

	1 (25%)

	0 (0%)

	0 (0%)

	0 (0%)

	1 (25%)

	0 (0%)

	0 (0%)

	0 (0%)

	
Prenatal diagnosis

	2

	0 (0%)

	0 (0%)

	0 (0%)

	1 (50%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	1 (50%)

	
Gonadectomy

	89

	9 (10%)

	26 (29%)

	18 (20%)

	6 (7%)

	2 (2%)

	5 (6%)

	1 (1%)

	12 (13%)

	3 (3%)

	1 (1%)

	6 (7%)

	
Asymptomatic

	2

	0 (0%)

	0 (0%)

	1 (50%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	1 (50%)

	0 (0%)

	0 (0%)

	0 (0%)

	
Appendicitis

	16

	0 (0%)

	4 (25%)

	2 (13%)

	3 (19%)

	0 (0%)

	2 (13%)

	0 (0%)

	3 (19%)

	2 (13%)

	0 (0%)

	0 (0%)

	
Loss of appetite

	40

	3 (8%)

	12 (30%)

	7 (18%)

	2 (5%)

	1 (3%)

	2 (5%)

	0 (0%)

	8 (20%)

	1 (3%)

	1 (3%)

	3 (8%)

	
Loss of weight

	28

	1 (4%)

	10 (36%)

	7 (25%)

	1 (4%)

	0 (0%)

	1 (4%)

	0 (0%)

	4 (14%)

	1 (4%)

	1 (4%)

	2 (7%)

	
Leukocytosis

	19

	3 (16%)

	4 (21%)

	5 (26%)

	1 (5%)

	0 (0%)

	2 (11%)

	0 (0%)

	1 (5%)

	3 (16%)

	0 (0%)

	0 (0%)

	
Fever

	5

	0 (0%)

	1 (20%)

	4 (80%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	
Constipation

	13

	1 (8%)

	1 (8%)

	3 (23%)

	2 (15%)

	0 (0%)

	1 (8%)

	0 (0%)

	1 (8%)

	1 (8%)

	0 (0%)

	3 (23%)

	
Vomit

	2

	0 (0%)

	0 (0%)

	1 (50%)

	0 (0%)

	0 (0%)

	0 (0%)

	1 (50%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	
Bleeding

	19

	1 (5%)

	6 (32%)

	3 (16%)

	3 (16%)

	0 (0%)

	2 (11%)

	0 (0%)

	2 (11%)

	0 (0%)

	0 (0%)

	2 (11%)

	
Abdominal distention

	39

	4 (10%)

	7 (18%)

	9 (23%)

	3 (8%)

	1 (3%)

	4 (10%)

	0 (0%)

	6 (15%)

	1 (3%)

	0 (0%)

	4 (10%)

	
Ascites

	10

	1 (10%)

	4 (40%)

	2 (20%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	3 (30%)

	
GCT

	72

	10 (14%)

	26 (36%)

	21 (29%)

	9 (13%)

	2 (3%)

	0 (0%)

	1 (1%)

	0 (0%)

	3 (4%)

	0 (0%)

	0 (0%)

	
Not GCT

	26

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	5 (19%)

	0 (0%)

	14 (54%)

	0 (0%)

	1 (4%)

	6 (23%)

	
Loculation

													
 Unilocular cyst

	0

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	
 Unilocular cyst + solid

	2

	0 (0%)

	1 (50%)

	0 (0%)

	0 (0%)

	0 (0%)

	1 (50%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	
 Multilocular cyst

	5

	0 (0%)

	0 (0%)

	2 (40%)

	1 (20%)

	0 (0%)

	1 (20%)

	0 (0%)

	0 (0%)

	0 (0%)

	1 (20%)

	0 (0%)

	
 Multilocular cyst + solid

	29

	3 (10%)

	9 (31%)

	6 (21%)

	2 (7%)

	1 (3%)

	0 (0%)

	1 (3%)

	2 (7%)

	2 (7%)

	0 (0%)

	3 (10%)

	
 Multilocular solid

	29

	2 (7%)

	4 (14%)

	13 (45%)

	2 (7%)

	0 (0%)

	2 (7%)

	0 (0%)

	4 (14%)

	0 (0%)

	0 (0%)

	2 (7%)

	
 Solid

	33

	5 (15%)

	12 (36%)

	0 (0%)

	4 (12%)

	1 (3%)

	1 (3%)

	0 (0%)

	8 (24%)

	1 (3%)

	0 (0%)

	1 (3%)

	
Compressed organs

	20

	5 (25%)

	6 (30%)

	3 (15%)

	1 (5%)

	0 (0%)

	1 (5%)

	0 (0%)

	2 (10%)

	1 (5%)

	0 (0%)

	1 (5%)

	
Grade

													
 1

		4 (10%)

	4 (10%)

	16 (41%)

	5 (13%)

	0 (0%)

	0 (0%)

	0 (0%)

	5 (13%)

	0 (0%)

	0 (0%)

	5 (13%)

	
 2

		1 (4%)

	9 (32%)

	5 (18%)

	3 (11%)

	1 (4%)

	3 (11%)

	1 (4%)

	4 (14%)

	0 (0%)

	1 (4%)

	0 (0%)

	
 3

		5 (17%)

	12 (41%)

	0 (0%)

	0 (0%)

	1 (3%)

	2 (7%)

	0 (0%)

	5 (17%)

	3 (10%)

	0 (0%)

	1 (3%)

	
 4

		0 (0%)

	1 (50%)

	0 (0%)

	1 (50%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	
Stage

													
 1

		1 (5%)

	2 (10%)

	6 (30%)

	4 (20%)

	1 (5%)

	2 (10%)

	0 (0%)

	2 (10%)

	0 (0%)

	1 (5%)

	1 (5%)

	
 2

		3 (7%)

	12 (27%)

	14 (31%)

	2 (4%)

	1 (2%)

	1 (2%)

	1 (2%)

	6 (13%)

	1 (2%)

	0 (0%)

	4 (9%)

	
 3

		3 (14%)

	6 (29%)

	1 (5%)

	2 (10%)

	0 (0%)

	2 (10%)

	0 (0%)

	4 (19%)

	2 (10%)

	0 (0%)

	1 (5%)

	
 4

		3 (25%)

	6 (50%)

	0 (0%)

	1 (8%)

	0 (0%)

	0 (0%)

	0 (0%)

	2 (17%)

	0 (0%)

	0 (0%)

	0 (0%)

	
Viruses

	20

	0 (0%)

	6 (30%)

	4 (20%)

	1 (5%)

	1 (5%)

	2 (10%)

	0 (0%)

	1 (5%)

	1 (5%)

	0 (0%)

	4 (20%)

	
Elevated tumor markers

	80

	10 (13%)

	26 (33%)

	11 (14%)

	7 (9%)

	2 (3%)

	4 (5%)

	1 (1%)

	10 (13%)

	3 (4%)

	1 (1%)

	5 (6%)

	
AC: Adenocarcinoma; CHOR: Choriocarcinoma; DYS: Dysgerminoma; EC: Embryonal carcinoma; GCT: Germ cell tumor; GrCT: Granulosa cell tumor; IT: Immature teratoma; LCH: Langerhans cell histiocytosis; n: No. of cases; RMS: Rhabdomyosarcoma; SEM: Seminoma; YST: Yolk sac tumor.

Table 3 The peculiarities observed in the different benign tumor types found in our study population, using percentages [n, (%)]

Peculiarities of benign tumors

	Total

	SCA

	MCA

	BCA

	AF

	Fibroma

	MT

	Gonadoblastoma

	SST

	Cysts

	
Age [years]

											
 Prepuberty (0–9)

	15

	2 (13%)

	1 (7%)

	0 (0%)

	0 (0%)

	0 (0%)

	6 (40%)

	0 (0%)

	0 (1%)

	6 (40%)

	
 Puberty (10–17)

	97

	15 (15%)

	9 (9%)

	3 (3%)

	1 (1%)

	2 (2%)

	18 (19%)

	1 (1%)

	1 (1%)

	47 (49%)

	
Sex

											
 Male

	7

	2 (29%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	2 (29%)

	0 (0%)

	0 (0%)

	3 (43%)

	
 Female

	105

	15 (14%)

	10 (10%)

	3 (3%)

	1 (1%)

	2 (2%)

	22 (21%)

	1 (1%)

	1 (1%)

	50 (48%)

	
Size [cm]

											
 <5

	27

	8 (30%)

	3 (11%)

	1 (4%)

	0 (0%)

	0 (0%)

	3 (11%)

	0 (0%)

	0 (0%)

	12 (44%)

	
 5–10

	63

	6 (10%)

	5 (8%)

	1 (2%)

	1 (2%)

	0 (0%)

	19 (30%)

	0 (0%)

	0 (0%)

	31 (49%)

	
 >10

	22

	3 (14%)

	2 (9%)

	1 (5%)

	0 (0%)

	2 (9%)

	2 (9%)

	1 (5%)

	1 (5%)

	10 (45%)

	
Tumor location

											
 Right

	47

	10 (21%)

	4 (9%)

	2 (4%)

	0 (0%)

	2 (4%)

	7 (15%)

	0 (0%)

	0 (0%)

	22 (47%)

	
 Left

	55

	6 (11%)

	5 (9%)

	1 (2%)

	1 (2%)

	0 (0%)

	16 (29%)

	0 (0%)

	1 (2%)

	25 (45%)

	
 Both sides

	10

	1 (10%)

	1 (10%)

	0 (0%)

	0 (0%)

	0 (0%)

	1 (10%)

	1 (10%)

	0 (0%)

	6 (60%)

	
Pain location

											
 Right

	31

	7 (22.6%)

	3 (9.7%)

	0 (0%)

	0 (0%)

	1 (3.2%)

	6 (19.4%)

	0 (0%)

	0 (0%)

	12 (38.7%)

	
 Left

	56

	7 (12.5%)

	7 (12.5%)

	1 (1.8%)

	0 (0%)

	0 (0%)

	15 (26.8%)

	0 (0%)

	1 (1.8%)

	28 (50%)

	
 Both sides

	20

	2 (10%)

	0 (0%)

	2 (10%)

	1 (5%)

	1 (5%)

	2 (10%)

	0 (0%)

	0 (0%)

	11 (55%)

	
Pain radiates to leg

	27

	6 (22%)

	4 (15%)

	1 (4%)

	1 (4%)

	0 (0%)

	10 (37%)

	1 (4%)

	0 (0%)

	4 (15%)

	
Repetition

	7

	1 (14%)

	0 (0%)

	2 (29%)

	0 (0%)

	1 (14%)

	1 (14%)

	0 (0%)

	0 (0%)

	2 (29%)

	
Prenatal diagnosis

	6

	1 (17%)

	1 (17%)

	1 (17%)

	0 (0%)

	0 (0%)

	1 (17%)

	0 (0%)

	0 (0%)

	2 (33%)

	
Gonadectomy

	27

	5 (19%)

	2 (7%)

	2 (7%)

	1 (4%)

	0 (0%)

	9 (33%)

	0 (0%)

	0 (0%)

	8 (30%)

	
Asymptomatic

	5

	1 (20%)

	1 (20%)

	0 (0%)

	0 (0%)

	0 (0%)

	1 (20%)

	0 (0%)

	0 (0%)

	2 (40%)

	
Appendicitis

	19

	2 (11%)

	4 (21%)

	1 (5%)

	0 (0%)

	1 (5%)

	2 (11%)

	0 (0%)

	0 (0%)

	9 (47%)

	
Loss of appetite

	19

	9 (47%)

	5 (26%)

	2 (11%)

	1 (5%)

	0 (0%)

	1 (5%)

	0 (0%)

	0 (0%)

	1 (5%)

	
Loss of weight

	5

	2 (40%)

	1 (20%)

	2 (40%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	
Leukocytosis

	35

	9 (26%)

	3 (9%)

	1 (3%)

	1 (3%)

	1 (3%)

	5 (14%)

	0 (0%)

	0 (0%)

	15 (43%)

	
Fever

	11

	1 (9%)

	2 (18%)

	0 (0%)

	0 (0%)

	1 (9%)

	2 (18%)

	0 (0%)

	0 (0%)

	5 (45%)

	
Constipation

	8

	2 (25%)

	1 (13%)

	0 (0%)

	0 (0%)

	0 (0%)

	2 (25%)

	0 (0%)

	0 (0%)

	3 (38%)

	
Vomit

	7

	0 (0%)

	2 (29%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	5 (71%)

	
Bleeding

	7

	0 (0%)

	2 (29%)

	0 (0%)

	1 (14%)

	1 (14%)

	1 (14%)

	0 (0%)

	0 (0%)

	2 (29%)

	
Abdominal distention

	24

	2 (8%)

	1 (4%)

	1 (4%)

	0 (0%)

	2 (8%)

	9 (38%)

	1 (4%)

	1 (4%)

	7 (29%)

	
Ascites

	4

	1 (25%)

	1 (25%)

	0 (0%)

	0 (0%)

	0 (0%)

	1 (25%)

	0 (0%)

	0 (0%)

	1 (25%)

	
GCT

	25

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	24 (96%)

	1 (4%)

	0 (0%)

	0 (0%)

	
Not GCT

	87

	17 (20%)

	10 (11%)

	3 (3%)

	1 (1%)

	2 (2%)

	0 (0%)

	0 (0%)

	1 (1%)

	53 (61%)

	
Loculation

											
 Unilocular cyst

	39

	5 (13%)

	1 (3%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	33 (85%)

	
 Unilocular cyst + solid

	20

	7 (35%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	4 (20%)

	1 (5%)

	0 (0%)

	8 (40%)

	
 Multilocular cyst

	28

	2 (7%)

	9 (32%)

	0 (0%)

	1 (4%)

	1 (4%)

	5 (18%)

	0 (0%)

	0 (0%)

	10 (36%)

	
 Multilocular cyst + solid

	21

	3 (14%)

	0 (0%)

	1 (5%)

	0 (0%)

	1 (5%)

	13 (62%)

	0 (0%)

	1 (5%)

	2 (10%)

	
 Multilocular solid

	4

	0 (0%)

	0 (0%)

	2 (50%)

	0 (0%)

	0 (0%)

	2 (50%)

	0 (0%)

	0 (0%)

	0 (0%)

	
 Solid

	0

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	
Compressed organs

	16

	6 (38%)

	2 (13%)

	1 (6%)

	0 (0%)

	0 (0%)

	1 (6%)

	0 (0%)

	0 (0%)

	6 (38%)

	
Viruses

	6

	2 (33%)

	0 (0%)

	0 (0%)

	0 (0%)

	0 (0%)

	2 (33%)

	0 (0%)

	1 (17%)

	1 (17%)

	
Elevated tumor markers

	8

	1 (13%)

	1 (13%)

	2 (25%)

	0 (0%)

	0 (0%)

	3 (38%)

	0 (0%)

	0 (0%)

	1 (13%)

	
AF: Adenofibroma; BCA: Borderline cystadenoma; GCT: Germ cell tumor; MCA: Mucinous cystadenoma; MT: Mature teratoma; n: No. of cases; SCA: Serous cystadenoma; SST: Sclerosing stromal tumor.

Table 4 Clinico-morphological presentation in children with malignant tumors in our study

Children with malignant tumors – clinico-morphological presentation

		
Peculiarities

	YST endodermal sinus pattern*

	IT #

	DYS $

	SEM %

	AC^

	CHOR &

	RMS @

	EC ¥

	LCH §

	GrCT ‡

	
Percent

	70%

	86%

	67%

	100%

	100%

	100%

	71%

	100%

	100%

	83%

	
Age [years]

											
 Prepuberty (0–9)

	67%

	88.9%

	50%

	0%

	100%

	0%

	57%

	100%

	100%

	100%

	
 Puberty (10–17)

	75%

	83.3%

	63%

	100%

	100%

	100%

	86%

	100%

	0%

	67%

	
Sex

											
 Male

	50%

	100%

	100%

	100%

	0%

	100%

		0%

	0%

	0%

	
 Female

	83%

	79%

	63%

	0%

	100%

	0%

	50%

	100%

	100%

	83%

	
Size [cm]

											
 <5

	100%

	100%

	50%

	0%

	100%

	0%

	50%

	100%

	0%

	0%

	
 5–10

	75%

	80%

	100%

	100%

	100%

	100%

	100%

	100%

	100%

	100%

	
 >10

	60%

	89%

	33%

	100%

	100%

	0%

	25%

	100%

	0%

	80%

	
Tumor location

											
 Right

	67%

	25%

	60%

	100%

	100%

	100%

	83%

	0%

	0%

	100%

	
 Left

	63%

	93%

	75%

	100%

	100%

	0%

	67%

	100%

	0%

	67%

	
 Both sides

	0%

	50%

	0%

	0%

	100%

	0%

	50%

	100%

	100%

	100%

	
Pain location

											
 Right

	67%

	100%

	80%

	100%

	100%

	100%

	80%

	0%

	0%

	100%

	
 Left

	67%

	85%

	33%

	0%

	100%

	0%

	80%

	100%

	0%

	100%

	
 Both sides

	100%

	75%

	100%

	100%

	100%

	0%

	50%

	100%

	100%

	50%

	
Pain radiates to leg

	100%

	83%

	100%

	0%

	100%

	0%

	100%

	100%

	0%

	100%

	
Repetition

	100%

	100%

	0%

	0%

	100%

	0%

	100%

	100%

	0%

	100%

	
Death

	0%

	0%

	100%

	0%

	0%

	0%

	100%

	0%

	0%

	0%

	
Prenatal diagnosis

	0%

	0%

	100%

	0%

	0%

	0%

	0%

	0%

	0%

	100%

	
Gonadectomy

	78%

	83%

	67%

	100%

	100%

	100%

	83%

	100%

	100%

	83%

	
Asymptomatic

	0%

	100%

	0%

	0%

	0%

	0%

	100%

	0%

	0%

	0%

	
Appendicitis

	0%

	100%

	100%

	0%

	100%

	0%

	100%

	100%

	0%

	0%

	
Loss of appetite

	100%

	100%

	100%

	100%

	100%

	0%

	100%

	100%

	100%

	100%

	
Loss of weight

	100%

	100%

	100%

	0%

	100%

	0%

	100%

	100%

	100%

	100%

	
Leukocytosis

	100%

	100%

	100%

	0%

	100%

	0%

	100%

	100%

	0%

	0%

	
Fever

	0%

	100%

	0%

	0%

	0%

	0%

	0%

	0%

	0%

	0%

	
Constipation

	100%

	100%

	100%

	0%

	100%

	0%

	100%

	100%

	0%

	100%

	
Vomit

	0%

	100%

	0%

	0%

	0%

	100%

	0%

	0%

	0%

	0%

	
Bleeding

	100%

	100%

	100%

	0%

	100%

	0%

	100%

	0%

	0%

	100%

	
Abdominal distention

	100%

	67%

	100%

	100%

	100%

	0%

	100%

	100%

	0%

	100%

	
Ascites

	100%

	100%

	0%

	0%

	0%

	0%

	0%

	0%

	0%

	100%

	
GCT

	70%

	86%

	67%

	100%

	0%

	100%

	0%

	100%

	0%

	0%

	
Not GCT

	0%

	0%

	0%

	0%

	100%

	0%

	71%

	0%

	100%

	83%

	
Loculation

											
 Unilocular cyst

	0%

	0%

	0%

	0%

	0%

	0%

	0%

	0%

	0%

	0%

	
 Unilocular cyst + solid

	0%

	0%

	0%

	0%

	100%

	0%

	0%

	0%

	0%

	0%

	
 Multilocular cyst

	0%

	100%

	100%

	0%

	100%

	0%

	0%

	0%

	100%

	0%

	
 Multilocular cyst + solid

	33%

	100%

	100%

	100%

	0%

	100%

	50%

	100%

	0%

	67%

	
 Multilocular solid

	100%

	77%

	50%

	0%

	100%

	0%

	75%

	0%

	0%

	100%

	
 Solid

	80%

	0%

	50%

	100%

	100%

	0%

	75%

	100%

	0%

	100%

	
Compressed organs

	100%

	100%

	100%

	0%

	100%

	0%

	100%

	100%

	0%

	100%

	
Grade

											
 1

	50%

	88%

	80%

	0%

	0%

	0%

	60%

	0%

	0%

	80%

	
 2

	100%

	80%

	33%

	100%

	100%

	100%

	75%

	0%

	100%

	0%

	
 3

	80%

	0%

	0%

	100%

	100%

	0%

	80%

	100%

	0%

	100%

	
 4

	0%

	0%

	100%

	0%

	0%

	0%

	0%

	0%

	0%

	0%

	
Stage

											
 1

	100%

	67%

	50%

	100%

	100%

	0%

	50%

	0%

	100%

	100%

	
 2

	33%

	93%

	100%

	100%

	100%

	100%

	50%

	100%

	0%

	75%

	
 3

	67%

	100%

	50%

	0%

	100%

	0%

	100%

	100%

	0%

	100%

	
 4

	100%

	0%

	100%

	0%

	0%

	0%

	100%

	0%

	0%

	0%

	
Viruses

	0%

	100%

	100%

	100%

	100%

	0%

	100%

	100%

	0%

	100%

	
Elevated tumor markers

	70%

	82%

	71%

	100%

	100%

	100%

	80%

	100%

	100%

	80%

	
AC: Adenocarcinoma; CHOR: Choriocarcinoma; DYS: Dysgerminoma; EC: Embryonal carcinoma; GCT: Germ cell tumor; GrCT: Granulosa cell tumor; IT: Immature teratoma; LCH: Langerhans cell histiocytosis; RMS: Rhabdomyosarcoma; SEM: Seminoma; YST: Yolk sac tumor. Peculiarities: *: Anastomosing network of labyrinthine-like spaces lined by primitive tumor cells; formation of vaguely glomeruloid perivascular structures, Schiller–Duval bodies. #: Mature elements from all three germ layers, mixed with immature elements, mostly neuroectodermal (variable amounts). $: Nests of large, uniform polygonal cells with clear cytoplasm and distinct cell membranes alveolar pattern; fibrous septa containing T-cells (cytotoxic), epithelioid histiocytes separating the tumors. %: Uniform cells with distinct borders and pale clear cytoplasm; fibrous septa with lymphocytes. ^: Invasion by malignant glands. &: Biphasic with large syncytiotrophoblasts and mononucleated cytotrophoblasts; distinct cell membrane and pale cytoplasm. @: Primitive mesenchymal and spindle cells with variable degrees of skeletal muscle differentiation. ¥: Solid, glandular growth pattern; cells are polygonal, crowded with cell (indistinct) borders, large and primitive. §: Langerhans cells with abundant, pale eosinophilic cytoplasm, irregular and elongated nuclei with prominent nuclear grooves and folds. ‡: Sheet of small, bland, cuboidal to polygonal cells with scanty cytoplasm; uniform angulated and often grooved nuclei.

Table 5 Clinico-morphological presentation in children with benign tumors in our study

Children with benign tumors – clinico-morphological presentation

	
Peculiarities

	SCA*

	MCA #

	BCA $

	AF %

	Fibroma^

	MT &

	Gonadoblastoma @

	SCT ¥

	Cysts §

	
Percent

	65%

	70%

	67%

	100%

	100%

	100%

	100%

	100%

	85%

	
Age [years]

										
 Prepuberty (0–9)

	50%

	100%

	0%

	0%

	0%

	100%

	0%

	0%

	100%

	
 Puberty (10–17)

	67%

	67%

	67%

	100%

	100%

	100%

	100%

	100%

	83%

	
Sex

										
 Male

	100%

	0%

	0%

	0%

	0%

	100%

	0%

	0%

	100%

	
 Female

	60%

	70%

	67%

	100%

	100%

	100%

	100%

	100%

	84%

	
Size [cm]

										
 <5

	75%

	100%

	0%

	0%

	0%

	100%

	0%

	0%

	83%

	
 5–10

	67%

	60%

	100%

	100%

	0%

	100%

	0%

	0%

	81%

	
 >10

	33%

	50%

	100%

	0%

	100%

	100%

	100%

	100%

	100%

	
Tumor location

										
 Right

	80%

	75%

	50%

	0%

	100%

	100%

	0%

	0%

	83%

	
 Left

	33%

	60%

	100%

	100%

	0%

	100%

	0%

	100%

	76%

	
 Both sides

	100%

	100%

	0%

	0%

	0%

	100%

	100%

	0%

	100%

	
Pain location

										
 Right

	57%

	100%

	0%

	0%

	100%

	100%

	0%

	0%

	75%

	
 Left

	71%

	57%

	100%

	0%

	0%

	100%

	0%

	100%

	93%

	
 Both sides

	100%

	0%

	50%

	100%

	100%

	100%

	0%

	0%

	91%

	
Pain radiates to leg

	100%

	100%

	100%

	100%

	0%

	100%

	100%

	0%

	100%

	
Repetition

	100%

	0%

	100%

	0%

	100%

	100%

	0%

	0%

	100%

	
Elevated tumor markers

	100%

	100%

	100%

	0%

	0%

	100%

	0%

	0%

	100%

	
Prenatal diagnosis

	100%

	100%

	100%

	0%

	0%

	100%

	0%

	0%

	100%

	
Gonadectomy

	100%

	100%

	100%

	100%

	0%

	100%

	 (0%

	0%

	100%

	
Asymptomatic

	100%

	100%

	0%

	0%

	0%

	100%

	0%

	0%

	100%

	
Appendicitis

	100%

	100%

	100%

	0%

	100%

	100%

	0%

	0%

	100%

	
Loss of appetite

	78%

	100%

	100%

	100%

	0%

	100%

	0%

	0%

	100%

	
Loss of weight

	100%

	100%

	100%

	0%

	0%

	0%

	0%

	0%

	0%

	
Leukocytosis

	89%

	100%

	100%

	100%

	100%

	100%

	0%

	0%

	80%

	
Fever

	100%

	100%

	0%

	0%

	100%

	100%

	0%

	0%

	100%

	
Constipation

	100%

	100%

	0%

	0%

	0%

	100%

	0%

	0%

	100%

	
Vomit

	0%

	100%

	0%

	0%

	0%

	0%

	0%

	0%

	100%

	
Bleeding

	0%

	100%

	0%

	100%

	100%

	100%

	0%

	0%

	100%

	
Abdominal distention

	100%

	100%

	100%

	0%

	100%

	100%

	100%

	100%

	100%

	
Ascites

	100%

	100%

	0%

	0%

	0%

	100%

	0%

	0%

	100%

	
GCT

	0%

	0%

	0%

	0%

	0%

	100%

	100%

	0%

	0%

	
Not GCT

	65%

	70%

	67%

	100%

	100%

	0%

	0%

	100%

	85%

	
Loculation

										
 Unilocular cyst

	100%

	0%

	0%

	0%

	0%

	0%

	0%

	0%

	85%

	
 Unilocular cyst + solid

	86%

	0%

	0%

	0%

	0%

	100%

	100%

	0%

	100%

	
 Multilocular cyst

	0%

	78%

	0%

	100%

	100%

	100%

	0%

	0%

	90%

	
 Multilocular cyst + solid

	0%

	0%

	0%

	0%

	100%

	100%

	0%

	100%

	0%

	
 Multilocular solid

	0%

	0%

	100%

	0%

	0%

	100%

	0%

	0%

	0%

	
 Solid

	0%

	0%

	0%

	0%

	0%

	0%

	0%

	0%

	0%

	
Compressed organs

	100%

	100%

	100%

	0%

	0%

	100%

	0%

	0%

	100%

	
Viruses

	100%

	0%

	0%

	0%

	0%

	100%

	0%

	100%

	100%

	
AF: Adenofibroma; BCA: Borderline cystadenoma; GCT: Germ cell tumor; MCA: Mucinous cystadenoma; MT: Mature teratoma; SCA: Serous cystadenoma; SST: Sclerosing stromal tumor. Peculiarities: *: Small, unilocular cysts lined by a single layer of tall, columnar cuboid epithelium, ciliated cells. #: Multilocular cystic neoplasm composed of multiple cysts and glands lined by a single layer of bland mucinous epithelium. $: Numerous slender to bulbous, irregularly contoured papillae with fibrous, myxoid cores and hierarchical branching pattern; pseudostratified, crowded and lined with epithelial tufting. %: Predominant fibrous stroma, with glands and cysts forming a minor component. ^: Well circumscribed unencapsulated, variably cellular fascicular storiform growth of tumor cells within discreet collagenous stroma. &: Mixture of mature, benign tissues composed of ectodermal, mesodermal and endodermal components in varying degrees. @: Primitive germ cells, sex cord stromal cells surrounded by ovarian type stroma. ¥: Alternating cellular and hypocellular areas impart a pseudo-lobular appearance. §: Conjunctive fibrous layer of cylindrical epithelium; inner layer of granulosa cell; eosinophilic cytoplasm; primordial follicle; primary and secondary follicles present

Table 6 Multinomial logistic regression of RRs and 95% CIs and p-values of risk factors found in our study among patients with malignant tumors, using patients with benign tumors as the control group

Patients’ risks

	Total ( n =210)

	Malignant tumor [ n , (%)]

	Univariate RR

	p -value

	95%CI

	Multivariate RR

	p -value

	95%CI

	
Obesity

	109

	72/98 (73.5%)

	2.78

	0.001

	1.93–4.00

	1.34

	0.001

	1.29–2.55

	
Mother’s age [years]

									
 ≤20

	24

	18/98 (18.4%)

	Constant

	Constant

	Constant

	Constant

	Constant

	Constant

	
 >20–25

	50

	17/98 (17.3%)

	0.40

	0.001

	0.24–0.63

	0.72

	0.100

	-3.26– -0.94

	
 >25–30

	60

	15/98 (15.3%)

	0.33

	0.001

	0.20–0.54

	0.69

	0.393

	-3.486– -1.182

	
 >30–35

	32

	18/98 (18.4%)

	0.73

	0.105

	0.50–1.06

	1.14

	0.660

	-2.239–0.213

	
 >35–40

	40

	30/98 (30.6%)

	0.95

	0.73

	0.71–1.27

	1.10

	0.680

	-1.468–1.027

	
Breastfeeding ≤5 months

	100

	72/98 (73.5%)

	3.20

	0.001

	2.20–4.63

	1.11

	0.001

	1.578–2.883

	
DSD

	17

	10/98 (10.2%)

	1.42

	0.104

	0.93–2.16

	0.79

	0.179

	-0.356–1.908

	
Stress

	97

	70/98 (71.4%)

	3.04

	0.001

	2.13–4.34

	1.33

	0.001

	1.526–2.824

	
Hormone

	21

	15/98 (15.3%)

	1.68

	0.001

	1.23–2.31

	1.16

	0.018

	1.217–2.345

	
Smoking

	96

	69/98 (70.4%)

	2.74

	0.001

	1.94–3.86

	1.36

	0.001

	1.329–2.594

	
Positive heredo-genetic history

	63

	47/98 (48.0%)

	2.24

	0.001

	1.71–2.92

	1.10

	0.001

	1.154–2.612

	
Abnormal birth weight

	34

	25/98 (25.5%)

	1.72

	0.001

	1.30–2.29

	1.08

	0.003

	1.442–2.104

	
Residence area

									
 Rural

	97

	59/98 (60.2%)

	1.82

	0.001

	1.33–2.49

	1.00

	0.001

	1.559–1.733

	
 Urban

	113

	39/98 (39.8%)

	
Pollution

	100

	70/98 (71.4%)

	2.98

	0.001

	2.08–4.25

	1.30

	0.022

	1.119–1.505

	
Rh positive

	159

	81 (82.7%)

	1.61

	0.037

	1.03–2.51

	1.11

	0.860

	-0.737–0.611

	
No postnatal vitamin D

	47

	20/98 (20.4%)

	0.80

	0.751

	0.25–2.68

	0.83

	0.855

	-0.964–0.430

	
No postnatal vaccination

	42

	18/98 (18.4%)

	0.86

	0.470

	0.58–1.29

	1.08

	0.453

	0.288–1.907

	
Menstrual disorders

	36

	25/98 (25.5%)

	1.62

	0.001

	1.21–2.18

	1.15

	0.001

	1.957–3.339

	
Malformations

	102

	77/98 (78.6%)

	4.07

	0.001

	2.67–6.20

	1.65

	0.001

	1.559–1.733

	
UTI

	85

	45/98 (45.9%)

	1.35

	0.049

	1.00–1.81

	1.28

	0.053

	0.006–1.146

	
CI: Confidence interval; DSD: Disorder of sex development; n: No. of cases; Rh: Rhesus; RR: Relative risk ratio; UTI: Urinary tract infection

Table 7 Multinomial logistic regression of estimation coefficient (β), 95% CIs and p-values of risk factors found in our study among patients with malignant tumors using patients with mixed GCT as the dependent variable

Risks

	n (%)

	IT

total n , β coefficient ( p -value)

	YST

total n , β coefficient ( p -value)

	DYS

total n , β coefficient ( p -value)

	GrCT

total n , β coefficient ( p -value)

	RMS

total n , β coefficient ( p -value)

	ADC

total n , β coefficient ( p -value)

	
Univariate

								
Obesity

	72 (73.5%)

	16, 0.04 (0.953)

	6, 0.08 (0.316)

	7, 0.045 (0.958)

	5, 0.40 (0.733)

	9, 0.62 (0.396)

	3, 0.80 (0.436)

	
Mother’s age [years]

								
 ≤20

	18 (18.4%)

	Constant

						
 >20–25

	17 (17.3%)

	3, 0.18 (0.872)

	0, -16.12 (0.994)

	2, -0.47 (0.736)

	0, 17.04 (0.995)

	5, 0.10 (0.100)

	0, 16.82 (0.990)

	
 >25–30

	15 (15.3%)

	5, 0.51 (0.629)

	2, -0.41 (0.733)

	0, -15.58 (0.994)

	0, 17.09 (0.994)

	2, -1.10 (0.309)

	0, 16.86 (0.995)

	
 >30–35

	18 (18.4%)

	5, 0.92 (0.403)

	2, 0.10 (1.000)

	2, 0.69 (0.624)

	2, 0.41 (0.726)

	2, -0.69 (0.535)

	0, 16.22 (1.000)

	
 >35–40

	30 (30.6%)

	6, 0.54 (0.600)

	4, 0.13 (0.901)

	4, 0.83 (0.519)

	1, 1.66 (0.207)

	1, -1.95 (0.129)

	3, 0.15 (0.889)

	
Breastfeeding ≤5 months

	72 (73.5%)

	12, -0.52 (0.393)

	7, 0.04 (0.964)

	7, 0.44 (0.626)

	6, 15.71 (0.992)

	12, 0.98 (0.262)

	5, 15.71 (0.993)

	
DSD

	10 (10.2%)

	2, -0.210 (0.824)

	1, 14.590 (0.991)

	4, 15.001 (0.100)

	1, 0.78 (0.437)

	0, -0.245 (0.802)

	0, -14.604 (0.994)

	
Stress

	70 (71.4%)

	15, 0.52 (0.454)

	6, 1.03 (0.206)

	5, 1.21 (0.147)

	3, 2.13 (0.033)

	11, 0.14 (0.868)

	5, 13.01 (0.983)

	
Hormone

	15 (15.3%)

	3, -0.36 (0.654)

	0, -15.2 (0.991)

	2, 0.18 (0.846)

	1, -0.18 (0.885)

	3, 0.14 (0.868)

	0, 15.27 (0.994)

	
Smoking

	69 (70.4%)

	13, 0.33 (0.599)

	6, -0.41 (0.600)

	6, -0.12 (0.886)

	4, -0.12 (0.903)

	12, 0.98 (0.262)

	1, 0.58 (0.630)

	
Positive heredo-genetic history

	47 (48.0%)

	8, -0.64 (0.284)

	6, 0.25 (0.740)

	3, -0.85 (0.295)

	1, -1.76 (0.130)

	7, -0.15 (0.816)

	3, 0.25 (0.800)

	
Abnormal birth weight

	25 (25.5%)

	4, -0.64 (0.363)

	4, 0.41 (0.600)

	2, -0.44 (0.626)

	1, -0.80 (0.497)

	4, -0.11 (0.885)

	0, -14.79 (0.989)

	
Residence area (rural)

	59 (60.2%)

	10, -0.91 (0.137)

	6, -0.41 (0.600)

	4, -1.03 (0.193)

	5, 0.80 (0.497)

	10, 0.11 (0.885)

	2, -1.22 (0.227)

	
Pollution

	70 (71.4%)

	10, 1.8 (0.010)

	6, 1.30 (0.124)

	6, 1.01 (0.257)

	5, 0.10 (0.938)

	13, 0.86 (0.463)

	3, 1.30 (0.221)

	
Rh positive

	81 (82.7%)

	8, 2.97 (0.001)

	10, 15.00 (1.000)

	9, 14.60 (0.993)

	6, 13.70 (1.000)

	14, 14.00 (0.992)

	5, 14.64 (0.995)

	
No postnatal vitamin D

	20 (20.4%)

	0, -15.28 (0.985)

	2, 0.18 (0.842)

	2, -0.05 (0.958)

	3, 1.20 (0.200)

	6, 0.92 (0.199)

	1, -0.18 (0.880

	
No postnatal vaccination

	18 (18.4%)

	8, 0.72 (0.267)

	1, -1.00 (0.389)

	1, -0.88 (0.450)

	1, -0.41 (0.733)

	0, -15.40 (0.988)

	0, -15.30 (1.000)

	
Menstrual disorders

	25 (25.5%)

	5, 0.87 (0.275)

	1, -0.16 (0.895)

	5, 2.26 (0.013)

	4, 2.73 (0.010)

	2, 0.25 (0.802)

	2, 1.63 (0.138)

	
Malformations

	77 (78.6%)

	18, 0.36 (0.655)

	7, -0.59 (0.490)

	8, 0.64 (0.582)

	4, -0.74 (0.457)

	9, 0.85 (0.257)

	5, 13.52 (0.986)

	
UTI

	45 (45.9%)

	11, -0.06 (0.920)

	4, -0.56 (0.459)

	3, -0.85 (0.295)

	2, -0.85 (0.373)

	9, 0.43 (0.525)

	1, -1.54 (0.194)

	
Multivariate

								
Stress

	70 (71.4%)

	15, 1.39 (0.114)

	6, 0.91 (0.276)

	5, 1.2 (0.180)

	3, 2.10 (0.048)

	11, 0.08 (0.926)

	5, 14.42 (0.990)

	
Pollution

	70 (71.4%)

	10, 1.75 (0.041)

	6,1.27 (0.138)

	6, 0.82 (0.388)

	5, 0.12 (0.930)

	13, 0.88 (0.452)

	3, 1.19 (0.277)

	
Rh positive

	81 (82.7%)

	8, 3.41 (0.001)

	10, 15.07 (0.100)

	9, 14.45 (0.994)

	6, 13.62 (0.100)

	14, 14.92 (0.993)

	5, 15.00 (0.900)

	
Menstrual disorders

	25 (25.5%)

	5, 0.95 (0.343)

	1, -0.25 (0.840)

	5, 2.22 (0.017)

	4, 2.80 (0.013)

	2, 0.26 (0.794)

	2, 1.46 (0.196)

	
AC: Adenocarcinoma; CI: Confidence interval; DSD: Disorder of sex development; DYS: Dysgerminoma; GCT: Germ cell tumor; GrCT: Granulosa cell tumor; IT: Immature teratoma; n: No. of cases; Rh: Rhesus; RMS: Rhabdomyosarcoma; UTI: Urinary tract infection; YST: Yolk sac tumor

Table 8 Multinomial logistic regression of estimation coefficient (β), 95% CIs and p-values of risk factors found in our study among patients with benign tumors, using patients with cysts as the dependent variable

Risks

	n

	SCA

total n , β coefficient ( p -value)

	MCA

total n , β coefficient ( p -value)

	MT

total n , β coefficient ( p -value)

	
Univariate

					
Obesity

	37

	4, 0.55 (0.426)

	7, 2.58 (0.001)

	10, 1.39 (0.014)

	
Mother’s age [years]

					
 ≤20

	7

	Constant

			
 >20–25

	36

	5, -0.236 (0.851)

	3, 15.688 (0.997)

	7, 0.10 (0.935)

	
 >25–30

	45

	5, -0.47 (0.708)

	4, 15.743 (0.997)

	10, 0.22 (0.854)

	
 >30–35

	14

	3, 0.811 (0.558)

	3, 17.246 (0.996)

	3, 0.81 (0.558)

	
 >35–40

	10

	3, 1.098 (0.437)

	0, 0.428 (1.000)

	3, 1.10 (0.437)

	
Breastfeeding ≤5 months

	28

	7, 2.46 (0.001)

	3, 1.97 (0.031)

	11, 2.65 (0.001)

	
DSD

	7

	2, 1.94 (0.124)

	2, 11.15 (0.985)

	0, -1.55 (0.214)

	
Stress

	27

	4, 1.33 (0.086)

	3, 1.66 (0.055)

	12, 2.51 (0.000)

	
Hormone

	6

	2, 1.94 (0.124)

	0, -11.15 (0.100)

	2, 1.55 (0.214)

	
Smoking

	27

	6, 1.12 (0.078)

	2, 0.34 (0.698)

	9, 1.22 (0.033)

	
Positive heredo-genetic history

	16

	3, 1.70 (0.077)

	3, 2.39 (0.017)

	4, 1.63 (0.072)

	
Abnormal birth weight

	9

	3, 2.41 (0.043)

	2, 2.57 (0.045)

	3, 2.01 (0.090)

	
Residence area (rural)

	38

	6, 0.32 (0.585)

	3, 0.08 (0.913)

	10, 0.59 (0.249)

	
Pollution

	30

	7, 1.91 (0.005)

	3, 1.41 (0.090)

	9, 1.75 (0.006)

	
Rh positive

	78

	11, 0.49 (0.393)

	9, 2.01 (0.056)

	24, 18.37 (0.993)

	
No postnatal vitamin D

	27

	7, 0.77 (0.192)

	4, 0.72 (0.319)

	0, -15.14 (0.983)

	
No postnatal vaccination

	24

	4, 0.55 (0.426)

	8, 3.11 (0.001)

	4, 0.12 (0.860)

	
Menstrual disorders

	11

	2, 0.49 (0.592)

	3, 1.66 (0.055)

	1, -0.63 (0.583)

	
Malformations

	25

	7, 2.15 (0.003)

	3, 1.66 (0.055)

	8, 1.81 (0.007)

	
UTI

	40

	5, -0.21 (0.728)

	6, 1.07 (0.130)

	7, -0.22 (0.678)

	
Multivariate

					
Breastfeeding ≤5 months

	28

	7, 2.53 (0.005)

	3, 1.68 (0.209)

	11, 1.85 (0.045)

	
Obesity

	37

	4, 0.27 (0.760)

	7, 2.84 (0.013)

	10, 1.55 (0.070)

	
Stress

	27

	4, 0.91 (0.382)

	3, 2.18 (0.100)

	12, 2.35 (0.008)

	
No postnatal vaccination

	24

	4, 0.89 (0.301)

	8, 3.71 (0.002)

	4, 1.08 (0.276)

	
Malformations

	25

	7, 1.96 (0.032)

	3, 1.44 (0.274)

	8, 2.18 (0.044)

	
CI: Confidence interval; DSD: Disorder of sex development; MCA: Mucinous cystadenoma; MT: Mature teratoma; n: No. of cases; Rh: Rhesus; SCA: Serous cystadenoma; UTI: Urinary tract infection

Table 9 Genetic and non-genetic related malformations observed in our study, comparing the malignant, and benign tumor groups

Congenital malformations

	Total ( n =102)

	Malignant tumors

77 (75%)

	Benign tumors

25 (25%)

	
Non-genetic malformations

	87

	67 (77%)

	20 (23%)

	
 Ureter and kidney: ureterocele, ureteral obstruction, hydronephrosis

	14

	10 (71%)

	4 (29%)

	
 Face–eye: myopia, nystagmus, astigmatism strabismus, blindness

	28

	18 (64%)

	10 (36%)

	
 Other facial defects: cleft lip, cleft palate, ear, nasal septal defect, micrognathism, retrognathia

	11

	11 (100%)

	0 (0%)

	
 Gonadal: hydrocele, cryptorchidism, micro-penis

	18

	17 (94%)

	1 (6%)

	
 Spleen: accessory spleen

	6

	4 (67%)

	2 (33%)

	
 Heart: atrial and ventricular septal defect, mitral valve anomalies

	18

	13 (72%)

	5 (28%)

	
 Integumentary–muscular: umbilical, inguinal, and diaphragmatic hernia, abdominal wall, neural tube defect

	11

	10 (91%)

	1 (9%)

	
 Skeletal: scoliosis, sacral, coccygeal, foot, forefoot and knee deformity

	18

	17 (94%)

	1 (6%)

	
 Ano-rectal: anorectal agenesis, fistulas, anal stenosis

	9

	9 (100%)

	0 (0%)

	
 Thyroid dysgenesis

	4

	4 (100%)

	0 (0%)

	
 Hydrocephalus

	1

	1 (100%)

	0 (0%)

	
 Lung and tracheal: bronchogenic cysts, tracheomalacia, bronchopulmonary sequestrations

	5

	5 (100%)

	0 (0%)

	
 Pancreas: annular pancreas and pancreaticobiliary malformation

	2

	2 (100%)

	0 (0%)

	
 Liver: choledochal cysts

	2

	2 (100%)

	0 (0%)

	
Genetic-related malformations

	28

	21 (75%)

	7 (25%)

	
 Down syndrome

	11

	10 (91%)

	1 (9%)

	
 Prader–Willi syndrome

	3

	3 (100%)

	0 (0%)

	
 Disorders of sexual development

	17

	10 (59%)

	7 (41%)

	
 Dwarfism

	5

	4 (80%)

	1 (20%)

	
 Osteogenesis imperfecta

	3

	3 (100%)

	0 (0%)

	

Rare cases

Case No. 1

A 1-year-old boy presented with a right testicular mass, palpated during physical examination, confirmed by ultrasound (US), with AFP (100 U/L) and β-HCG (420 mU/mL). We excised the mass, and HP examination revealed intratubular germ cell neoplasia (ITGCN). Macroscopic: 1/1/0.3 cm and 2/1/1 cm tissues, caffeine-white and elastic. Microscopic: testicular parenchyma with seminiferous tubules, Periodic Acid Schiff (PAS-positive) and p53, voluminous nuclei, hyperchromatic nucleolus, cells proliferated with cytoplasm forming (dis)continuing layers with immature portions of juvenile Sertoli cells. He was discharged but returned at age three with tumor recurrence on the same testis. An orchiectomy was performed, and an HP examination showed a MT. Macroscopic: 3/2/2 cm and 3/2/1 cm nodes, grayish-translucent irregular tissue of various consistency and non-homogenous areas. Microscopic: testicular parenchyma with seminiferous tubules lined by Sertoli and germinal cells, squamous epithelium, acini seromucinous, pseudostratified ciliated epithelium of intestinal type, and muscular tissue components (Figure 4, A and B).

Figure 4 Microscopic description of Case No. 1: (A) A section of the testis tumor with an area of intratubular neoplasm; (B) A section of the testis tumor containing mature teratoma with intestinal epithelium, muscle tissue. Hematoxylin–Eosin (HE) staining: (A and B) ×100

Case No. 2

A girl aged 17 presented with abdominal pain, and her physical and radiological examination confirmed a left ovarian mass. The tumor was excised, and the HP result revealed sclerosing stromal tumor. Macroscopic: irregular fragmented tissue 4/3/3cm, whitish gray and elastic. Microscopic: parenchyma with solid tumoral proliferation and pseudolobular pattern separates cells, having hypocellular areas through dense bands of collagen stroma tissues. Hemangiopericytoma-like areas, thin wall vessels, fusiform, round cells with clear cytoplasm, and various stages of follicles were observed (Figure 5A).

Case No. 3

A 15-year-old girl presented with bleeding and abdominal pain. Physical examination and US confirmed left ovarian mass, thick septations, and solid areas with flow. The tumor was excised, and HP examination results suggested fibroma. Macroscopic: white and elastic tissue fragments (1/1/0.3 cm and 1/1/0.5 cm). Microscopic: benign tumor proliferation with solid patterns containing fascicles, fusiform cell bands, dispose of storiform and oval nuclei, curly, pointy end, few eosinophile cytoplasm, and discreet collagen bands (Figure 5B).

Case No. 4

A boy aged 15 presented with a left testicular mass (4/5 cm), not painful at palpation, and US confirmed tumoral formation; hence, tumor excision was performed, and HP results reported MT. AFP (5 U/L), β-HCG (3 mU/mL). Macroscopic: 2/3/3.5 cm fragment with multicystic aspects, elastic, coffee white. Microscopic: proliferated tumor of testicular tissues containing squamous epithelium, muscular tissue, seromucinous acini epithelium, ciliated epithelium, intestinal, and respiratory type. The patient returned in two months with tumor recurrence on the same testes, still not painful at palpation. Computed tomography (CT) scan confirmed a 4/4.5 cm mass, orchidectomy was performed, chemotherapy was administered, and the HP results showed RMS (embryonal). Macroscopic: 2/3/4 cm fragments, grayish white, encapsulated, and elastic. Microscopic: tumoral proliferation with solid pattern, pseudocapsular fibrosis, mesenchymal, fusiform, and syncytiotrophoblast cells, alternate hyper-hypocellular areas, storiform-myxoid areas, few cytoplasm, oval nuclei. IHC staining: positive vimentin, desmin, α-SMA, Myf4, Ki67 (20%) (Figure 5, C–E).

Case No. 5

An 11-year-old girl presented with abdominal distention and pain. US and CT scan revealed an abdominal tumor of 30/22/21 cm, painful at palpation, 11/10 cm mass on the left lung, and solid nodules on the diaphragm left hepatic duct, bladder, kidney, right pleural base, noted pleuritis, pericarditis, and right perihilar renal adenopathy. AFP (8543 U/L), β-HCG (24611 mU/mL), CA-125 (258 U/mL), NSE (76 ng/mL). Stage IVB gigantic GCT from both ovaries was suspected. Chemotherapy [Maligne Keimzelltumoren (MAKEI) 2005] with three PEI (Cisplatin, Etoposide and Ifosfamide) cycles was administered; afterward, adenopathies were absent, reduced pericardial fluids and tumor by 8%, revealing a feeding artery from the left posterior tract and two external iliac arteries. Oophorectomy, salpingectomy, and excision of four hepatic and two peritoneal metastases were performed, tumor markers normalized, and the patient was discharged and still lives healthy. HP examination showed macroscopic: 3/2/1 cm, 6/2/1 cm, 9/5/1 cm irregular tissue, 20/18/6 cm encapsulated tissue, polylobulated and non-homogenous, yellow and brown cystic space, with jelly content and elastic. Microscopic: tumor proliferation with polymorphic contents, areas of embryonal carcinoma (10%), mature and IT (50%), YST (35%), and choriocarcinoma (5%). Cells had variable cytoplasm, irregular nuclei, hyaline globule, calcification, and hemosiderin pigment. Liver, kidney, and bladder metastases with fibrotic proliferation, as in the tumor described above, and hemosiderin pigment was observed (Figure 6, A–E).

Figure 5 HE-stained histopathology slides of patients with rare gonadal tumors in our study: (A) Sclerosing stromal tumor – hypocellular areas composed of dense collagen; (B) Fibroma – bland spindled to ovoid nuclei with pointy ends and scant eosinophilic cytoplasm; (C) MT with intestinal and respiratory epithelium, muscle tissue; (D) Testicular MT – respiratory epithelium seromucinous acini, muscle tissue; (E) Rhabdomyosarcoma – fascicles of spindle cells. HE staining: (A and B) ×400; (C) ×50; (D and E) ×200. MT: Mature teratoma

Figure 6 Histological sections of a mixed GCT: (A) Yolk sac tumor; (B) Mature teratoma with respiratory epithelium; (C) Mixed GCT composed of immature teratoma; (D) Embryonal carcinoma – sheets and nests of large primitive cells; (E) Choriocarcinoma – multi-nucleated, large syncytiotrophoblasts surrounded by mononucleated trophoblasts. HE staining: (A, B and E) ×100; (C) ×200; (D) ×400. GCT: Germ cell tumor

Case No. 6

A 16-year-old girl presented with pleurisy, abdominal pain, and distention. US and CT scan showed a left ovarian mass; hence, a midline laparotomy and oophorectomy were performed, the right ovary was autoamputated, and chemotherapy three PEI cycles were administered. HP examination revealed stage III mixed GCT. Macroscopic: 19/14/10 cm, 3/2/1 cm, 5/10 cm fragments with nodular formations, encapsulated with multicystic aspect, containing solid and gelatinous greyish-red content, ununiformed areas, elastic and predominantly tough consistency, greyish-caffeine zone. Microscopic: tumoral formation of MT (25%) with tissues from ectoderm, endoderm, and mesoderm layers; immature tissue aspects from three embryonic layers with grade III IT (60%) predominantly neuroepithelium subform rosette; YST areas (15%), microcystic, papillary and glandular forms, and necrohemorrhagic areas. IHC staining: positive AFP, PAS, vimentin, Ki67 (10%) in solid areas. Markers were normal post-chemotherapy. The patient returned two years later, presenting with abdominal pain towards the upper quadrant, we suspected tumor metastasis requiring chemotherapy. The CT scan examination revealed multiple perihepatic tumor formations; hence, we performed exploratory laparotomy, tumor excision, biopsy, and HP examination, which revealed a MT, pointing to growing teratoma syndrome. The patient was later discharged, and to date, the tumor has never reoccurred. Macroscopic: irregular tissues 3/2/1 cm, 4/3/1 cm, and 2/1/1 cm, with caffeine-grayish zones. First, an unencapsulated fragment, mildly non-homogenous, elastic, with zones of adipose cartilage; the second fragment was cystic with 0.2–0.4 cm wall thickness and translucent liquid; and a third multi-cystic fragment. Microscopic: proliferated tumor tissue had components of mesoderm, endoderm, and ectoderm layers (Figure 7, A–D).

Figure 7 Histopathology slides and description of Case No. 6: (A) Yolk sac tumor – anastomosing channels and variably sized cysts lined by primitive tumor cells with various amounts of clear to eosinophilic cytoplasm; (B) Germ cell tumor metastasis – after therapy was metastasized the MT, squamous epithelium, muscle tissue; (C) High-power view shows the immature teratoma component, with the presence of immature neural tissue; (D) Metastasis – MT with the presence of squamous epithelium. HE staining: (A and D) ×200; (B) ×100; (C) ×400. MT: Mature teratoma

Discussions

There are risk factors for gonadal tumors, identifying and avoiding them could lead to early tumor detection and treatment, and also prevent tumor occurrence. Smoking is known to cause gonadal malignant tumors in children by mutating germ cells; in contrast, Wang et al. reported that exposure to smoking causes a high risk of malignancy in adulthood, suggesting a progression process of carcinogenesis from childhood [15, 16]. Studies have also confirmed that hepatitis, herpesvirus, and HIV are oncoviruses [17]. Furthermore, menstrual disorders or bleeding are recognized risk factors for epithelial and SCSTs [18].

In our study, the highest estimation coefficient (β) was stress and menstrual disorders as a risk of developing GrCTs (Table 7), while pollution and Rh positive for ITs. For benign tumors, obesity and no postnatal vaccination were risks for MCA; stress and malformations were for MT, and breastfeeding ≤5 months for SCA. A group of studies showed smoking is a risk factor for MCA, obesity for SCA, chronic menstrual irregularities, infertility, congenital malformation for MT, obesity, DSD, positive heredo-genetic history, and hormones intake for GrCT, and for IT risk factors included advanced mother’s age, low birthweight, irregular menstrual cycles, cryptorchidism, hypospadias, and a very high number of patients had ear, face and neck malformation [19, 20, 21]. From the previous study, an extremely high risk [odds ratio (OR) 93.70] of developing GCT was observed only in children with facial malformations [21]. Similar to these results, in our study, facial malformations were the highest type of malformation among patients (Table 9). This is important to note, as malformation is a high-risk factor of childhood malignancy, knowing the mechanism leading to malformation also leads to malignancy; genetic-related malformation also has a higher GCT risk [22].

Biro & Deardorff explain that due to numerous developmental transformations at puberty, there are more possibilities during this period for abnormal tumor cell development [23]; likewise, in our study, 73% of patients were in puberty.

One of our patients had a recurrence of benign pre-pubertal pure MT after a 2-year history of ITGCN. Contrary to our finding, Skakkebæk reported that most GCTs originate from ITGCN as a precursor, having a malignancy risk of 50% in five years, except for pediatric YSTs and MTs [24, 25]. Additionally, in our study, we observed a malignant transformation of prepubertal MT into RMS. Literature shows that the malignant transformation of a GCT into a non-GCT is rare, with 1–3% occurrence in MT [26]. Research which supports our findings reports that large tumors (11.4 cm mean), elevated CA-125, aging, and menopause are risk factors for malignant transformation of MT, which can occur 15–20 years after MT diagnoses [27]. In terms of environmental risk factors, other studies have obtained results similar to our findings, showing that fertilizer’s nitrate, metals mining facilities, and insecticide chemicals (i.e., Dichlorodiphenyltrichloroethane) increase gonadal malignancy risk in a child, and even in that child’s offspring [28, 29, 30]. Goff et al. showed a reoccurrence of loss of appetite, distended abdomen, UTI, and abdomino-pelvic pain within a month, even before a one-year period may be a sign of malignancy [6]. In our study, only eight patients were prenatally diagnosed, suggesting that other cases may have been missing due to numerous developmental activities. This may also point to postnatal tumorigenesis in most patients or external risk factors. Similar to our study, other researchers have recognized hormones, especially estrogens, as a risk factor for gonadal malignant tumor, if the exposure length is >5 years [30, 31].

Furthermore, studies reported that high-income countries have higher tumor incidence but also higher access to treatment, hence reducing mortality rate or tumor progression, unlike patients in rural areas [14, 32]. Our study confirms this, as 75% of patients with stage IV tumors were from the rural area. Also, meta-analysis confirms obesity before menopause as a malignancy risk, and adults who were obese in childhood were at a higher risk of having malignant tumors, pointing to childhood as the start of tumorigenesis [33, 34].

Our study showed that children breastfed ≤5 months had a risk (RR: 1.11) of gonadal malignancy, this agrees with a study which showed that long-term breastfeeding reduces malignancy in mothers and children (leukemia) [35]. In our study, 71.4% of malignant patients were exposed to stress before diagnosis. A review had a similar result to ours, indicating that long-term stress, anxiety, suppressed anger, and depression promote tumorigenesis, quickening its progression through inflammation and damage of the tumor protein gene and deoxyribonucleic acid (DNA) [36, 37].

Study’s limits

Firstly, it is a retrospective study; also, being a pediatric population and a rare disease, we could not perform preoperative biopsies in >90%, but the intraoperative staging and postoperative HP examination for diagnoses were performed, being a standard, reliable method. We had an unequal population per tumor type; however, in total we had a good population size, and could present substantial results. A more extensive study to confirm our results will be helpful.

Conclusions

Malformations, smoking, pollution, obesity, and stress are the top five risk factors of pediatric malignant gonadal tumors, especially DYS, IT, and GrCT. Avoiding these risk factors will help reduce childhood (para)gonadal tumors. ≥70% of children who present with bleeding, (multilocular) solid (para)gonadal tumors, viruses, elevated markers, and weight loss have a high chance of having gonadal malignancy, especially mixed GCT, IT, and DYS.

Conflict of interests

The authors declare no conflict of interests.

Source of funding

No funding or financial support was received for making and publishing this article.

Ethics approval

This study was performed in compliance with all institutional policies, according to the Helsinki Declaration’s tenets, Romania’s regulations, Medical Research Council Guidelines for Good Clinical Practice in Clinical Trials, WMA, WHO Guidelines, approved by the Ethical Committees of the Emergency Children Hospitals of Timişoara, Iaşi, Arad and Bacău (Approval No. 124/2020-16922 on 11.12.2020) and the Scientific Research Ethics Commission (Approval No. 59/12.12.2018).
==== Refs
References

1 Baroni T Arato I Mancuso F Calafiore R Luca G On the origin of testicular germ cell tumors: from gonocytes to testicular cancer Front Endocrinol (Lausanne) 2019 10 343 343 31244770
2 Giona S Chapter 9: The epidemiology of testicular cancer Barber N Urologic cancers 2022 Brisbane, Australia Exon Publications 107 116
3 van Heerden Tjalma WA The multidisciplinary approach to ovarian tumours in children and adolescents Eur J Obstet Gynecol Reprod Biol 2019 243 103 110 31683108
4 Huang J Chan WC Ngai CH Lok V Zhang L Lucero-Prisno DE Xu W Zheng ZJ Elcarte E Withers M Wong MCS; Worldwide burden, risk factors, and temporal trends of ovarian cancer: a global study Cancers (Basel) 2022 14 9 2230 2230 35565359
5 National Childhood Cancer Registry (NCCR) Explorer Compare cancer sites 5-year age-adjusted incidence rates, and incidence rates by age at diagnosis, 2016-2020, ages < 20 An interactive website for NCCR Cancer Statistics 2023 Rockville, MD, USA National Cancer Institute (NCI)
6 Goff BA Mandel LS Drescher CW Urban N Gough S Schurman KM Patras J Mahony BS Andersen MR Development of an ovarian cancer symptom index: possibilities for earlier detection Cancer 2007 109 2 221 227 17154394
7 Price RA Stranges E Elixhauser A Pediatric cancer hospitalizations, 2009 Healthcare Cost and Utilization Project (HCUP) Statistical Briefs 2012 Rockville, MD, USA Agency for Healthcare Research and Quality, US Department of Health & Human Services
8 McGarvey N Gitlin M Fadli E Chung KC Increased healthcare costs by later stage cancer diagnosis BMC Health Serv Res 2022 22 1 1155 1155 36096813
9 Romanian Society of Pediatric Onco-Hematology Executive Report 2010-2021 2023 Cluj-Napoca, Romania National Registry of Pediatric Onco-Hematology 1 68
10 National Registry of Pediatric Onco-Hematology (NRPOH) Survival in pediatric cancers in Romania 2023 Bucharest, Romania NRPOH 1 25
11 Gatta G Botta L Rossi S Aareleid T Bielska-Lasota M Clavel J Dimitrova N Jakab Z Kaatsch P Lacour B Mallone S Marcos-Gragera R Minicozzi P Sánchez-Pérez MJ Sant M Santaquilani M Stiller C Tavilla A Trama A Visser O Peris-Bonet R; Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5 - a population-based study Lancet Oncol 2014 15 1 35 47 24314616
12 American Cancer Society (ACS) Cancer Facts & Figures 2024 ACS 2024 Atlanta, GA, USA ACS 1 82
13 Le Cornet Lortet-Tieulent J Forman D Béranger R Flechon A Fervers B Schüz J Bray F Testicular cancer incidence to rise by 25% by 2025 in Europe? Model-based predictions in 40 countries using population-based registry data Eur J Cancer 2014 50 4 831 839 24369860
14 World Health Organization (WHO) Childhood cancer inequalities in the WHO European Region 2022 Copenhagen, Denmark WHO Regional Office for Europe
15 Beal MA Yauk CL Marchetti F From sperm to offspring: assessing the heritable genetic consequences of paternal smoking and potential public health impacts Mutat Res Rev Mutat Res 2017 773 26 50 28927533
16 Wang T Townsend MK Vinci C Jake-Schoffman DE Tworoger SS Early life exposure to tobacco smoke and ovarian cancer risk in adulthood Int J Epidemiol 2021 50 3 965 974 33647961
17 Schiller JT Lowy DR An introduction to virus infections and human cancer Recent Results Cancer Res 2021 217 1 11 33200359
18 Cirillo PM Wang ET Cedars MI Chen LM Cohn BA Irregular menses predicts ovarian cancer: prospective evidence from the child health and development studies Int J Cancer 2016 139 5 1009 1017 27082375
19 Jordan SJ Green AC Whiteman DC Webb PM Risk factors for benign serous and mucinous epithelial ovarian tumors Obstet Gynecol 2007 109 3 647 654 17329516
20 Shamsudeen S Dunton CJ Granulosa theca cell tumors of the ovary StatPearls [Internet] 2024
21 Hall C Ritz B Cockburn M Davidson TB Heck JE Risk of malignant childhood germ cell tumors in relation to demographic, gestational, and perinatal characteristics Cancer Epidemiol 2017 46 42 49 28013088
22 Norwood MS Lupo PJ Chow EJ Scheurer ME Plon SE Danysh HE Spector LG Carozza SE Doody DR Mueller BA Childhood cancer risk in those with chromosomal and non-chromosomal congenital anomalies in Washington State: 1984-2013 PLoS One 2017 12 6 0179006 0179006
23 Biro FM Deardorff J Identifying opportunities for cancer prevention during preadolescence and adolescence: puberty as a window of susceptibility J Adolesc Health 2013 52 5 Suppl S15 S20 23601607
24 Skakkebæk NE Atypical germ cells in the adjacent "normal" tissue of testicular tumours Acta Pathol Microbiol Scand A 1975 83 1 127 130 1124645
25 Risk MC Masterson TA Intratubular germ cell neoplasms of the testis and bilateral testicular tumors: clinical significance and management options Indian J Urol 2010 26 1 64 71 20535289
26 Qin L Zhao T Liu X Wang H Gu X Chen D Wang Z He D Malignant transformation arising from mature ovarian cystic teratoma: a case series Medicine 2021 100 13 e24726 e24726 33787574
27 Park CH Jung MH Ji YI Risk factors for malignant transformation of mature cystic teratoma Obstet Gynecol Sci 2015 58 6 475 480 26623411
28 Donham KJ Chapter 14: International agricultural safety and health Donham KJ Agricultural medicine: rural occupational and environmental health, safety, and prevention 2nd 2016 Hoboken, NJ, USA Wiley-Blackwell 465 502
29 Fernández-Navarro P García-Pérez J Ramis R Boldo E López-Abente G Proximity to mining industry and cancer mortality Sci Total Environ 2012 435-436 66 73 22846765
30 Li H Liu Y Wang Y Zhao X Qi X Hormone therapy for ovarian cancer: emphasis on mechanisms and applications (Review) Oncol Rep 2021 46 4 223 223 34435651
31 Fénichel P Chevalier N Is testicular germ cell cancer estrogen dependent? The role of endocrine disrupting chemicals Endocrinology 2019 160 12 2981 2989 31617897
32 Weeks KS Lynch CF West M McDonald M Carnahan R Stewart SL; Impact of rurality on stage IV ovarian cancer at diagnosis: a Midwest Cancer Registry cohort study J Rural Health 2020 36 4 468 475 32077162
33 Liu Z Zhang TT Zhao JJ Qi SF Du P Liu DW Tian QB The association between overweight, obesity and ovarian cancer: a meta-analysis Jpn J Clin Oncol 2015 45 12 1107 1115 26491203
34 Weihe P Spielmann J Kielstein H Henning-Klusmann J Weihrauch-Blüher S Childhood obesity and cancer risk in adulthood Curr Obes Rep 2020 9 3 204 212 32519271
35 Stuebe A The risks of not breastfeeding for mothers and infants Rev Obstet Gynecol 2009 2 4 222 231 20111658
36 Dai S Mo Y Wang Y Xiang B Liao Q Zhou M Li X Li Y Xiong W Li G Guo C Zeng Z Chronic stress promotes cancer development Front Oncol 2020 10 1492 1492 32974180
37 Thomas SP Groer M Davis M Droppleman P Mozingo J Pierce M Anger and cancer: an analysis of the linkages Cancer Nurs 2000 23 5 344 349 11037954
